News About: Pharm. Industry
Green Cross pushing to acquire foreign vaccine maker
Green Cross plans to take over a foreign pharmaceutical firm producing vaccines within this year, Meritz Securities reported on September 13.
“We are waiting for a good chance to increase its annual sales by 100 bi...
Bayer Korea punished for exaggerated ads
The Korea Food and Drug Administration has recently reproved Bayer Korea for advertising its vitamin product Redoxon chewable tablet from December last year to April this year, although the company was ordered not to ...
Peptron wins Australia patent for once-weekly anti-diabetic agent
Peptron Inc. says it recently won Australia patent for sustained release formulation of exenatide (codename: PT302). The firm won a Korean patent in February 2008.
Exenatide is the first and only approved incretin ...
BC World, CJ CheilJedang to co-market meropenem 1g in Korea
BC World Pharm and CJ CheilJedang will co-market meropenem 1g in the domestic market valued at 30 billion won, after holding a launching symposium on September 9.
Meropenem an ultra-broad spectrum injectable antibiot...
Neuronex’s NXCL-4950 wins global technology award
Neuronex Co., a Korean biopharmaceutical co company, says its peripheral blood vessel vasodilator ‘NXCL-4950’ received a special technology award in the 10th Moscow International Salon of Innovations and Investments, ...
Boryung seeking sales of 100 billion won with new antihypertensive
Boryung Pharmaceutical Co., one of Korea's largest pharmaceutical companies, said on September 9 that its newly approved fimasartan, a new angiotensin II receptor blocker, is expected to generate 100 billion won ($87 ...
Korea eying artificial joint markets
Influenced by the rising demand for artificial joints at home and abroad, the Korea Food and Drug Administration is making all-out to support the earliest launching of medical devices which are/will be produced by Kor...
Fimasartan, new hypertensive agent, receives marketing approval in Korea
Boryung Pharmaceutical Co., one of Korea's largest pharmaceutical companies, announced on September 9 that they received marketing approval from the Korean Food and Drug Administration (KFDA) for fimasartan, their new...
Foreign investors keen on pharmaceutical shares
Pharmaceutical shares are emerging as the new leading themes of the stock market this year as foreign investors has recently been at the forefront of purchasing pharmaceutical shares.
The U.S. based FID Low Priced ...
4 drug makers spend over 10 billion won on advertisement
Details of Korean company spending on advertisement revealed recently show that four pharmaceutical firms, such as Ildong Pharm, Dongkook Pharm, Myungin Pharm and Dong-A Pharm, spent more than 10 billion won in the fi...
